Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
AIGEN Sciences is a South Korean startup focused on AI-driven drug discovery. Built on its proprietary large biomedical model technology, the company provides end-to-end AI acceleration solutions for small molecule drug discovery, with the core goal of cutting the traditional 2-3 year lead candidate discovery cycle down to less than 6 months. Its core team has solid industry backgrounds: the algorithm lead developed BioBERT, the most highly cited model in biomedical NLP to date, and all members of the drug discovery team come from leading South Korean pharmaceutical companies, with hands-on experience developing multiple approved drugs.
The platform offers three main categories of AI tools:
The platform has a well-balanced team that combines cutting-edge bio-AI algorithm expertise with extensive hands-on drug development industry experience. Its technology has strong real-world applicability, and the improvement in R&D efficiency is proven and clear.
The official website only displays brand and team information, with no public pricing, detailed product specifications or trial access. It only accepts partnership inquiries from business clients, which makes it unfriendly to small and medium-sized R&D teams, and it does not support a Chinese language interface.
The website can currently be accessed directly via the public internet, no VPN proxy required. It is suitable for R&D teams at domestic Chinese pharmaceutical companies to contact for partnership evaluation.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on aigensciences.com official site.
aigensciences.com is an Unknown AI Apps provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of China direct-connect friendly. Click "Visit Official Site" to reach aigensciences.com directly.